Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

12.23 -0.58 (-4.53%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
19 20 Next >
Novocure Stock Dips As Q1 Earnings Miss Estimates, Higher Costs Hurt Bottom Line
 
Via Benzinga
NovoCure: Q1 Earnings Insights
 
Via Benzinga
Novocure Reports First Quarter 2023 Financial Results
From Novocure
Via Business Wire
The 3 Most Promising Healthcare Tech Stocks for April 2023
The best healthcare tech stocks provide investors with impressive upside potential, while promising to improve the healthcare sector. 
Via InvestorPlace
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Novocure
Via Business Wire
What 4 Analyst Ratings Have To Say About NovoCure
 
Via Benzinga
2 Best Defensive Stocks to Buy in March
These two defensive stocks should shine in the event of a marketwide correction. 
Via The Motley Fool
NovoCure Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
From Novocure
Via Business Wire
Novocure to Report First Quarter 2023 Financial Results
From Novocure
Via Business Wire
Kristin Stafford Joins Novocure Board of Directors
From Novocure
Via Business Wire
Why NovoCure Stock Is Falling Today
Investors were looking for a stronger Q4 from the cancer company. 
Via The Motley Fool
NovoCure (NVCR) Q4 2022 Earnings Call Transcript
NVCR earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Why Novocure Stock Was so Healthy Today
There was good news from the laboratory on Hump Day. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
 
Via Benzinga
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
From Novocure
Via Business Wire
Why Novocure Stock Is Sliding Today
Investors reacted negatively to the oncology treatment specialist's game of C-suite musical chairs. 
Via The Motley Fool
Will Novocure Stock Sink or Soar in 2023?
The stock has both soared and sank already this year. 
Via The Motley Fool
Why Novocure Stock Is Sinking Today
The company provided a disappointing sneak peek at its Q4 results. 
Via The Motley Fool
2 Stocks That Could Rebound and Rise 30% or More in 2023
They're down, but they aren't yet out. 
Via The Motley Fool
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
From Novocure
Via Business Wire
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
From Novocure
Via Business Wire
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
From Novocure
Via Business Wire
Novocure Round-Trips Its Recent Breakout After Announcing A Series Of C-Suite Changes
A series of unexpected C-suite changes sent shares diving again. 
Via Investor's Business Daily
Novocure Announces Organizational Changes to Prepare for Future Growth
From Novocure
Via Business Wire
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Novocure Has Fallen More Than 20% Over Seven Days — Why It Fell From Grace
Shares have given back a chunk of their 69% single-day gain on a lung cancer study. 
Via Investor's Business Daily
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
From Novocure
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.